• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase II study of edatrexate in advanced head and neck cancer. A Southwest Oncology Group study.

作者信息

Kuebler J P, Benedetti J, Schuller D E, Ensley J, Grunberg S M, Muirhead M J, Richert-Boe K E, Marshall M E

机构信息

Riverside Methodist Hospitals, Columbus, OH, USA.

出版信息

Invest New Drugs. 1994;12(4):341-4. doi: 10.1007/BF00873052.

DOI:10.1007/BF00873052
PMID:7775138
Abstract

Fifty-two patients with persistent, recurrent and/or metastatic squamous cell cancer of the head and neck were treated with weekly edatrexate, 80 mg/m2. Nine patients had received previous adjuvant or neoadjuvant chemotherapy. Of the 46 eligible patients, two complete responses and one partial response were observed (6%, 95% confidence interval of 1-18%). The most common toxicities were myelosuppression and mucositis, but dermatologic toxicity was also observed in 25% of patients. Edatrexate appears to have limited activity in advanced head and neck cancer.

摘要

相似文献

1
Phase II study of edatrexate in advanced head and neck cancer. A Southwest Oncology Group study.
Invest New Drugs. 1994;12(4):341-4. doi: 10.1007/BF00873052.
2
Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.依达曲沙与甲氨蝶呤治疗转移性和/或复发性头颈部鳞状细胞癌患者的随机III期试验：欧洲癌症研究与治疗组织头颈部癌症合作组研究
J Clin Oncol. 1995 Jul;13(7):1649-55. doi: 10.1200/JCO.1995.13.7.1649.
3
A phase II trial of edatrexate in previously treated squamous cell cervical cancer: a Gynecologic Oncology Group study.依托曲沙在既往接受过治疗的宫颈鳞状细胞癌中的II期试验：一项妇科肿瘤学组研究。
Am J Clin Oncol. 1997 Feb;20(1):78-80. doi: 10.1097/00000421-199702000-00017.
4
A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative Group.一项针对新型抗叶酸药物10-乙基-10-脱氮氨基蝶呤治疗晚期和/或复发性头颈部鳞状细胞癌患者的II期试验。欧洲癌症研究与治疗组织头颈癌合作组。
Ann Oncol. 1992 Mar;3(3):223-6. doi: 10.1093/oxfordjournals.annonc.a058156.
5
Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck.
Invest New Drugs. 1994;12(4):327-31. doi: 10.1007/BF00873049.
6
Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy.10-EdAM用于头颈部鳞状细胞癌患者的II期研究，这些患者此前未接受过化疗。
Invest New Drugs. 1992 Apr;10(1):31-4. doi: 10.1007/BF01275477.
7
A phase II trial of edatrexate in previously treated ovarian cancer. A Gynecologic Oncology Group study.一项针对既往接受过治疗的卵巢癌患者的依托泊苷Ⅱ期试验。一项妇科肿瘤学组的研究。
Am J Clin Oncol. 1995 Apr;18(2):164-6. doi: 10.1097/00000421-199504000-00015.
8
Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study.拓扑替康用于复发性或转移性头颈部鳞状细胞癌患者的评估。西南肿瘤协作组的一项II期研究。
Invest New Drugs. 1996;14(4):403-7. doi: 10.1007/BF00180818.
9
Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124).依达曲沙用于复发或难治性生殖细胞肿瘤的II期试验：一项西南肿瘤协作组研究（SWOG 9124）
Invest New Drugs. 1998;16(4):347-51. doi: 10.1023/a:1006128024879.
10
Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.抗叶酸药物依达曲沙与顺铂两种给药方案的I期及药理学研究。
Clin Cancer Res. 2001 Mar;7(3):501-9.

引用本文的文献

1
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.从甲氨蝶呤到培美曲塞及其他。抗叶酸药物的药效学和临床特性综述。
Invest New Drugs. 2006 Jan;24(1):37-77. doi: 10.1007/s10637-005-4541-1.

本文引用的文献

1
New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models.10-脱氮-氨基蝶呤系列的新型叶酸类似物。在腹水型和实体瘤小鼠模型中，与甲氨蝶呤相比，抗肿瘤疗效显著提高的进一步证据。
Cancer Chemother Pharmacol. 1984;12(1):26-30.
2
New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.10-脱氮氨基蝶呤系列的新型叶酸类似物：与母体化合物和甲氨蝶呤相比，10-乙基类似物对裸鼠体内某些人肿瘤异种移植瘤的抗肿瘤活性显著增强。
Cancer Treat Rep. 1985 May;69(5):551-3.
3
Toxic dermatitis induced by 10-ethyl-10-deaza-aminopterin (10-EdAM), a novel antifolate.
新型抗叶酸剂10-乙基-10-脱氮氨基蝶呤（10-EdAM）诱发的中毒性皮炎
Cancer. 1990 Nov 1;66(9):1910-3. doi: 10.1002/1097-0142(19901101)66:9<1910::aid-cncr2820660909>3.0.co;2-2.
4
Comparative study of the sensitivity of head and neck cell lines to methotrexate (MTX) and the analog 10-ethyl, 10-deazaaminopterin (10-EdAM).头颈部细胞系对甲氨蝶呤（MTX）和类似物10-乙基-10-脱氮氨基蝶呤（10-EdAM）敏感性的比较研究。
Otolaryngol Head Neck Surg. 1990 Jan;102(1):20-5. doi: 10.1177/019459989010200104.
5
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.顺铂加氟尿嘧啶与卡铂加氟尿嘧啶对比甲氨蝶呤治疗晚期头颈部鳞状细胞癌的随机对照研究：西南肿瘤协作组研究
J Clin Oncol. 1992 Aug;10(8):1245-51. doi: 10.1200/JCO.1992.10.8.1245.
6
Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy.10-EdAM用于头颈部鳞状细胞癌患者的II期研究，这些患者此前未接受过化疗。
Invest New Drugs. 1992 Apr;10(1):31-4. doi: 10.1007/BF01275477.
7
A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative Group.一项针对新型抗叶酸药物10-乙基-10-脱氮氨基蝶呤治疗晚期和/或复发性头颈部鳞状细胞癌患者的II期试验。欧洲癌症研究与治疗组织头颈癌合作组。
Ann Oncol. 1992 Mar;3(3):223-6. doi: 10.1093/oxfordjournals.annonc.a058156.